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ABSTRACT 
 
The capability to derive endothelial cell (ECs) from induced Pluripotent 
Stem (iPS) cells holds huge therapeutic potential for cardiovascular dis-
ease. Objective- This study elucidates the precise role of the RNA-binding 
protein Quaking isoform 5 (QKI-5) during EC differentiation from both 
mouse and human iPS cells and dissects how RNA-binding proteins can 
improve differentiation efficiency towards cell therapy for important vas-
cular diseases. iPS cells represent an attractive cellular approach for regen-
erative medicine today since they can be used to generate patient-specific 
therapeutic cells towards autologous cell therapy. In this study, using the 
model of iPS cells differentiation towards ECs, the QKI-5 was found to be 
an important regulator of STAT3 stabilisation and VEGFR2 activation during 
the EC differentiation process. QKI-5 was induced during EC differentiation, 
resulting in stabilisation of STAT3 expression and modulation of VEGFR2 
transcriptional activation as well as VEGF secretion through direct binding 
to the 3’ UTR of STAT3. Importantly, mouse iPS-ECs overexpressing QKI-5 
significantly improved angiogenesis and neovascularization and blood flow 
recovery in experimental hind limb ischemia. Notably, human iPS cells 
overexpressing QKI-5, induced angiogenesis on Matrigel plug assays in vivo 
only seven days after subcutaneous injection in SCID mice. These results 
highlight a clear functional benefit of QKI-5 in neovascularization, blood 
flow recovery and angiogenesis. They, thus, provide support to the grow-
ing consensus that elucidation of the molecular mechanisms underlying EC 
differentiation will ultimately advance stem cell regenerative therapy and 
eventually make the treatment of cardiovascular disease a reality. STEM 
CELLS 2017; 00:000–000 
 
 
SIGNIFICANCE STATEMENT 
 
Cardiovascular disease is a leading cause of mortality worldwide with pa-
thology being driven by the dysfunction of endothelial cells (ECs). Induced 
pluripotent stem (iPS) cell technology is offering new avenues to generate 
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ECs. Although there has been sig-
nificant progression in the field, 
currently, there are not any fully 
defined protocols in existence 
aimed at  generating high-fidelity, 
stable ECs. We provide robust evi-
dence that the RNA-binding pro-
tein QKI has a unique role in inducing EC differentiation from iPS cells and 
remarkably improving angiogenesis, neovascularization and blood flow re-
covery (almost 100%) in an in vivo model of vascular regeneration. These 
findings can advance stem cell regenerative therapy towards the treatment 
of cardiovascular disease. 
Subject Codes: iPS Cells; endothelial cell differentiation, vascular disease, 
angiogenesis, QKI-5. 
 
 
INTRODUCTION 
 
Cardiovascular disease is a leading cause of mortality 
worldwide with pathology being significantly driven by 
progressive vascular endothelial cell (EC) dysfunction 
which regulates key pathogenic events such as infiltra-
tion of inflammatory cells, vascular smooth muscle pro-
liferation and platelet aggregation  [1, 2]. As cardiovas-
cular disease progresses, ECs become depleted from 
the vascular lumen, and, without adequate replace-
ment, non-perfusion and tissue ischaemia ensues. Re-
pair and regeneration of ECs has been an important 
research focus for many years. As an important thera-
peutic avenue, the delivery of adult progenitor or stem 
cells to repair damaged vasculature has faced many 
limitations, such as identification and availability of ap-
propriate, efficacious cell-types for therapy [3]. Howev-
er, recently, the ability to derive ECs from induced plu-
ripotent stem (iPS) cells has extended the scientific 
scope for regenerative medicine  [4, 5]. 
Cell reprogramming is offering new avenues for re-
generative medicine with iPS cells proving able to dif-
ferentiate into nearly all types of cells within the body  
[6-8]. This is a unique characteristic of iPS cell technolo-
gy, which offers a significant potential for cell-based 
therapies towards repairing tissues or organs destroyed 
by injury, degenerative diseases, aging or cancer  [4, 5, 
8, 9]. Generation of iPS cells also offers a promising 
strategy to create patient-specific cells  [10-12]  [7, 13] 
with building evidence that these cells have therapeutic 
efficacy in animal models of disease  [5, 14]  [15]  [16]  
[3]. The concept of cell reprogramming is powerful  [17-
20] and has, so far, allowed the development of dynam-
ic approaches to generate functional cells of interest 
and to switch cell fate  [20]. We and others have recent-
ly demonstrated novel strategies of direct reprogram-
ming towards functional ECs  [21, 22].  Both iPS cells 
and directly reprogrammed cells (partial iPS –PiPS cells) 
can serve as useful tools not only for derivation of func-
tional cells but also for establishing efficient protocols 
of differentiation and developing platforms to investi-
gate the underlying mechanisms. 
Vascular cell differentiation is achieved through the 
coordination of diverse molecular pathways [21, 23-28]. 
Due to this, there is a need to better understand the 
complex dynamics behind RNA regulation and how this, 
in turn, influences transcriptional control and protein 
expression. Elucidation of these complex molecular sig-
nals, which are evoked during iPS and PiPS cell differen-
tiation towards ECs, may allow specific targeting of their 
activities to enhance cell differentiation and promote 
tissue regeneration. In an effort to elucidate the imper-
ative mechanisms of RNA regulation during EC differen-
tiation from iPS cells, the present study focused on the 
RNA-binding protein Quaking (QKI). QKI is a member of 
the “STAR” (signal transduction and activation of RNA) 
family of proteins. These proteins are characterized by 
the presence of at least one RNA-binding motif (QKI 
containing a KH domain), SH2 and SH3 domains and 
potential phosphorylation sites. This suggests their in-
volvement in signal transduction pathways  [29]  [30], 
pre-mRNA splicing  [31], exportation of mRNAs from the 
nucleus  [32], protein translation and mRNA stability. 
Functional studies of the mouse QKI gene have revealed 
that it has a key function in embryonic blood vessel 
formation and remodeling  [33]  [34, 35]. During vascu-
lar cell differentiation and reprogramming processes, 
QKI could play an important regulatory role in gene ex-
pression at the post-transcriptional level in either a 
miRNA-dependent or independent manner. Alternative 
splicing of genes, a process that RNA binding proteins 
are highly involved in, generates many forms of mature 
mRNA from the same gene is an essential process in 
development and a potent way to regulate gene ex-
pression at a post-transcriptional level.  QKI has a num-
ber of alternative splicing isoforms, three of which have 
been associated with vascular development; QKI-5, QKI-
6 and QKI-7.  This further reinforces the importance of 
QKI in protein regulation and development.  Each iso-
form contains identical RNA binding domains and differ 
only by their carboxy-terminal ends  [36, 37].  In this 
study we focus on the QKI splicing isoform 5, (QKI-5).  
QKI-5 is most highly expressed during EC differentiation 
from iPS cells, it is an essential player during embryo-
genesis and notably, QKI-5 null mice are embryonic le-
thal [38, 39]. 
We provide strong evidence that QKI-5 plays a criti-
cal role in the differentiation of ECs derived from iPS 
cells and acts as a key regulator of CD144 stabilization 
and VEGFR2 activation through STAT3 signaling. The 
RNA binding protein QKI-5 directly binds to 3’ UTR of 
STAT3 and induced STAT3 mRNA stabilisation. Remark-
ably, QKI-5 improved neovascularization and blood flow 
recovery in a hind limb ischemic model. Notably, human 
iPS cells overexpressing QKI-5 induced angiogenesis in 
Matrigel plug assays in vivo only seven days after subcu-
taneous injection in SCID mice, highlighting, thus, a piv-
otal role of QKI-5 in neovascularization, blood flow re-
covery and angiogenesis. 
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MATERIALS AND METHODS 
 
Cell culture media, serum, and cell culture supplements 
were purchased from ATCC, Millipore, LONZA, and 
Thermo Fisher Scientific. Antibodies against VE-cadherin 
(CD144) (ab33168), PECAM (CD31) (ab28364), Flk-1 
(ab9530), STAT3 (ab119352), pSTAT3 (ab76315), JAK-1 
(ab47435), GAPDH (ab8245), OCT4 (ab19857), eNOS 
(ab66127), QKI (ab126742) were purchased from 
Abcam. Antibodies against vWF (SC-8068), QKI (SC-
103851) were purchased from Santa Cruz. Antibodies 
against QKI-5 (AB 9904) were purchased from Millipore. 
 
Mouse iPS and ES cell Culture and Differenti-
ation 
Mouse iPS cells were generated in our laboratory using 
a similar approach as previously described  [40, 41]. 
Mouse iPS cells were cultured in gelatin-coated flasks 
(PBS containing 0.02% gelatin from bovine skin; Sigma-
Aldrich) in DMEM (ATCC) supplemented with 10% fetal 
bovine serum, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin (Thermo Fisher Scientific), 10 ng/ml re-
combinant human leukemia inhibitory factor (Milli-
pore); and 0.1 mM 2-mercaptoethanol (Invitrogen) in a 
humidified incubator supplemented with 5% CO2. The 
cells were passaged every 2 days at a ratio of 1:6. Dif-
ferentiation of iPS cells was induced by seeding the cells 
on type IV mouse collagen (5 μg/ml)-coated dishes in 
differentiation medium (DM) containing α-MEM sup-
plemented with 10% FBS (Invitrogen), 0.05 mM 2-
mercaptoethanol, 100 units/ml penicillin, and 100 
μg/ml streptomycin in the presence of 25 ng/ml VEGF 
for the time points indicated. 
 
Human iPS cells differentiation and HUVECs 
Human iPS cells were pre-differentiated in low attach-
ment plates using StemPro serum free media supple-
mented with BMP4, Activin A, FGF and VEGF for 5 days. 
The pre-differentiated cells were seeded on fibronectin 
(Sigma-Aldrich), whilst KDR endothelial precursor cells 
were magnetically sorted on day 6 using MicroBeads Kit 
(Miltenyi BIotec) and culturing in EGM-2 media (LONZA) 
for 3 to 9 days. QKI-5 was overexpressed or knockdown 
by lentiviral gene transfer on day 3 after KDR selection 
and the cells were harvested on day 3 and subjected to 
further analysis or labeled for the in vivo Matrigel plug 
assays. HUVECs were seeded on collagen I coated plates 
and cultured in EGM-2 media. QKI-5 was overexpressed 
by lentiviral gene transfer and subjected to further 
analysis. 
 
Experimental hind limb ischemia 
The mouse hind limb ischemia model was performed as 
previously described  [21, 42]. iPS-ECs were infected 
with FUW-QKI-5 or control empty vectors on day 4 of EC 
differentiation. 48 h later the cells were trypsinised and 
labelled with Molecular Probes Vybrant Cell Labelling 
(MP22885) before being injected intramuscularly into 
the adductors of C57BL/6 wild type mice. 
 
Statistical Analysis 
Data are expressed as the mean±SEM and were ana-
lyzed using GraphPad Prism 5 software with a two-
tailed Student's t test for two groups or pairwise com-
parisons or ANOVA. A value of *: p<0.05. * p<0.05, ** 
p<0.01, *** p<0.001 was considered significant. 
 
Detailed Methods and Materials are in SI Ap-
pendix, Experimental Procedures 
 
RESULTS 
 
 
 
Pluripotent stem cells differentiation towards 
endothelial cells 
Mouse iPS cells were differentiated towards ECs by 
seeding on collagen IV and differentiation media (DM) 
supplemented with 25 ng/ml Vascular Endothelial 
Growth Factor (VEGF) (DM+V) for 2 to 10 days. The dif-
ferentiated ECs adopted a typical EC morphology (Fig. 
1A-B). The efficiency of EC differentiation from mouse 
iPS cells was very high as FACs analysis is shown in Fig. 
1C (86.7% positive cells for CD144 (VE-Cadherin), and 
87.2% positive cells for CD31 were obtained). These 
results were confirmed in both mRNA (Fig. 1D) and pro-
tein levels (Fig. 1E, F). During EC differentiation the plu-
ripotent marker OCT4 was suppressed allowing the ex-
pression of the EC specific markers CD144 and CD31 to 
occur in a time point dependent manner (Fig. 1F). In-
deed, immunofluorescence confocal microscope images 
revealed that ECs derived from iPS cells expressed EC 
markers (CD144, FLK-1, eNOS and vWF) which are char-
acteristic of ECs (Fig. 1G). We also observed that the 
expression of the transcription factor STAT3 which is a 
known essential player in VEGF signaling during vascular 
development. We are reporting that STAT3 was pro-
gressively induced during EC differentiation (Fig. 1H). 
Taken together, this data clearly demonstrates that 
mouse iPS cells have been differentiated towards ECs 
based on a highly efficient approach. 
 
The RNA-binding protein QKI is induced dur-
ing EC differentiation from iPS cells 
QKI-5 was significantly induced during EC differentiation 
from iPS cells and this occurred in parallel with the EC 
markers CD144 and CD31 (Fig. 2A). It is important to 
note that only QKI-5 mRNA splicing isoform was in-
duced during EC differentiation. QKI-6, and QKI-7 ex-
pression levels were also tested showing no change or 
decrease, respectively (Figure 2A). Time-course experi-
ments also demonstrated that QKI-5 was progressively 
induced after 4 days post-differentiation from iPS cells 
(Fig. 2B). There was a comparable induction of CD144 
QKI-5 regulates EC differentiation and angiogenesis 
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and STAT3 (Fig. 2B). Immunofluorescence images 
demonstrated that the alternative splicing isoform QKI-
5 was localized to the EC nucleus in both mouse iPS-
derived ECs and in HUVECs (Fig. 2C-E). Also in both EC-
types, CD144 and CD31 were expressed in the plasma 
membrane (Fig. 2D and E). These results demonstrated 
that QKI-5 expression is induced during EC differentia-
tion from mouse iPS cells, and its expression is main-
tained in mature ECs. 
A number of additional experiments were per-
formed to determine whether QKI-5 plays a regulatory 
role in iPS cell differentiation towards ECs. Initially, a 
pure population (100%) of differentiated ECs was ob-
tained based on CD144 selection, as it is a robust EC-
specific marker. Based on this pure population of ECs 
derived from iPS cells, a high expression of QKI-5 was 
observed and this was comparable to the EC markers 
CD144, VEGFA, and the transcription factor STAT3 (Sup-
plementary Fig. S1 A-F). 
Further experiments performed on mouse embryon-
ic stem cells (ES cells) differentiated to ECs, using a simi-
lar approach as the iPS cells, verified that QKI-5 expres-
sion was induced in parallel with CD144 expression 
(Supplementary Fig. S2 A-D). These results indicated 
that QKI-5 may be implicated in differentiation of ECs 
derived from mouse iPS and ES cells. In order to eluci-
date the underlying mechanisms regulated by QKI-5 in 
EC differentiation, QKI-5 was overexpressed by lentiviral 
gene transfer at day 4 of EC differentiation using ECs 
derived from iPS cells. The cells were harvested on day 
6 and subjected to further analysis. QKI-5 overexpres-
sion significantly enhanced expression of the endotheli-
al markers CD144, CD31, eNOS, VEGFA and the tran-
scription factor STAT3 (Fig. 2F and G). Surprisingly, QKI-
5 overexpression also induced the in activation of the 
CD144 (VE-Cadherin) promoter as revealed by luciferase 
assays (Fig. 2H). 
Importantly, QKI-5 also induced the expression of 
the arterial specific EC marker Ephrin B2, but it did not 
affect the expression of venous (CoupTFII), and lym-
phatic (Lyve1) markers. Moreover, QKI-5 induced EC 
differentiation in an EC-specific manner, while markers 
of other cells lineages such as neuronal (Nestin), cardiac 
(Mef2c) or smooth muscle cell (SMA) were not altered 
by QKI-5 overexpression (Fig. 2I). This data reveal that 
QKI-5 induced EC differentiation towards an arterial 
lineage. 
 
QKI-5 is capable of initiating EC differentia-
tion from iPS cells 
Further experiments have revealed that QKI-5 leads to 
the stabilization of VE-Cadherin adhesion molecule dur-
ing the EC differentiation process. When differentiated 
ECs were treated with Actinomycin D for 6 hours or 
cyclohexamide for 24 hours, CD144 (VE-Cadherin) ex-
pression was stabilized in the presence of QKI-5 (Sup-
plementary Fig. S3A-B and S3C-D), respectively). More-
over, when differentiated ECs were treated with Acti-
nomycin D in a time point experiment from 0 to 24 
hours CD144 expression was stabilised as a decay curve 
is shown in Supplementary Figure S3E. These results 
demonstrate that QKI-5 induced the expression and 
stabilisation of CD144 during EC differentiation. Addi-
tional experiments have been conducted to address the 
important question whether QKI-5 is able to initiate EC 
differentiation from iPS cells. When QKI-5 was overex-
pressed in undifferentiated iPS cells, the cells started 
expressing the arterial marker Ephrin B2 3 days later, 
while venous, lymphatic or markers of other cell line-
ages, such as Nestin and SMA, were not expressed 
(Supplementary Fig. S4A). Importantly, EC markers were 
highly induced upon QKI-5 overexpression in early stag-
es of EC differentiation (Supplementary Fig. S4B). Final-
ly, to shed light on the upstream signaling, which acti-
vates QKI-5 expression in early stages of EC differentia-
tion from iPS cells, transcription factor binding analysis 
on the QKI-5 promoter has predicted a potential binding 
site for the transcription factor ETS1. ETS factors, and  in 
particular ETS1 and Etv2, have been reported as key 
factors that regulate endothelial development  [43]. 
Interestingly, ETS1 is induced during EC differentiation 
from iPS cells in a time dependent manner (Supplemen-
tary Fig. S4C), while overexpression of ETS1 in early 
stages of EC differentiation has led to induction of QKI-5 
(Supplementary Fig. S4D).  These results demonstrate 
that QKI-5 is able to initiate EC differentiation from iPS 
cells, and ETS1 may be implicated in the activation of 
QKI-5 in the early stages of EC differentiation. 
 
QKI-5 induced VEGF Receptor 2 (VEGFR2) ac-
tivation and VEGF secretion through direct 
binding of the 3’UTR region of STAT3 
Formation of vascular networks are highly dependent 
on VEGF as a critical regulator of EC differentiation and 
vasculogenesis during development. Overexpression of 
QKI-5 by lentiviral gene transfer induced the secretion 
of VEGF on day 6 during the EC differentiation process 
(Fig. 3A). Likewise, QKI-5 overexpression led to activa-
tion of VEGFR2 during EC differentiation from iPS cells 
(Fig. 3B). In order to shed light on the signaling cascade 
initiated by the VEGFR transcriptional activation, the 
expression of the transcription factors STAT3, JAK-1 and 
AP-1 was assessed. Over-expression of QKI-5 leads to 
enhanced transcriptional activation of the VEGFR2 sig-
naling pathway, which seems to be related to increased 
expression of VEGFA and autocrine stimulation of its 
cognate receptor (Fig. 3C). Notably, overexpression of 
QKI-5 induced the expression of EC markers, CD144 and 
CD31, in parallel with the induction of JAK-1, STAT3 and 
phosphorylation of STAT3 (Fig. 3D, and quantification in 
3E). These results revealed that QKI-5 is implicated in 
the activation of the VEGFR2-regulatory binding sites 
AP1, STAT3 as well as STAT3 phosphorylation. Addition-
al experiments were performed to investigate the na-
ture of QKI-5-mediated activation of VEGFR. When 
STAT3 was knocked down by shRNA during EC differen-
tiation, the previously observed upregulation of EC 
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markers (CD144, CD31, eNOS) and VEGFA, mediated by 
QKI-5, was ablated (Fig. 3F). Furthermore, luciferase 
assays revealed that knockdown of STAT3 by shRNA 
ablated the QKI-5-mediated activation of VEGFR2 (Sup-
plementary Fig. S5A). In agreement with the above re-
sults, when the differentiated ECs were treated with 
inhibitors to block the JAK-1, and STAT3 pathways, QKI-
5 did not activate the EC markers CD31, CD144, eNOS, 
FLK-1 (VEGFR2) and VEGFA (Supplementary Fig. S5B). 
Taken together, these data demonstrate that QKI-5 
modulates the activation of VEGFR and EC differentia-
tion through the transcription factor STAT3. Interesting-
ly, the KH DOMAIN-mutant QKI-5 constructs did not 
induce the expression of the EC markers, and STAT3 
signalling when it was overexpressed in the iPS cells 
(Supplementary Fig S6A-D). These results suggest that 
QKI-5 binds candidate RNAs in the JAK1-STAT3 signalling 
pathway and regulates EC differentiation. Importantly, 
luciferase assays have shown that QKI-5 activated the 
3’UTR of STAT3. Remarkably, QKI-5 was unable to acti-
vate the 3’UTR of STAT3 when the QKI motif was delet-
ed (Figure 3G). Moreover, RNA binding assays have con-
firmed that QKI binds directly to the 3’UTR of STAT3 
(Figure 3G, lower panel). Moreover, when differentiat-
ed ECs were treated with Actinomycin D in a time point 
experiment from 0 to 24 hours STAT3 expression was 
stabilized as a decay curve is shown in Figure 3H.  These 
results clearly demonstrate that the RNA binding pro-
tein QKI-5 induced VEGF Receptor 2 (VEGFR2) activation 
and VEGF secretion through direct binding of the 3’UTR 
of STAT3. 
 
QKI-5 has a critical role during EC differentia-
tion and vascular tube formation 
When QKI-5 expression was suppressed by shRNA dur-
ing EC differentiation, this resulted in a significant sup-
pression of the EC markers CD144 and CD31 (Fig. 4A 
and 4B) and the transcription factor STAT3 (Fig. 4B). 
Moreover, knockdown of QKI-5 caused inhibition in the 
transcriptional activation of VEGFR (Fig. 4C). Further-
more, knockdown of QKI-5 by shRNA resulted in inhibi-
tion of angiogenesis in Matrigel plugs in vivo (Fig. 4D), 
which further reinforced the notion that QKI-5 plays a 
critical role during EC differentiation and subsequent 
angiogenic function of the derived cells. 
 
QKI-5 induced angiogenesis in both in vitro 
and in vivo 
QKI-5 appears to play an important role in iPS cell-
derived ECs during the formation of vascular networks 
in vitro and in vivo. These processes are greatly de-
pendent on the presence of VEGF, although these ex-
periments were conducted in the absence of exogenous 
VEGF. Notably, overexpression of QKI-5 by lentiviral 
gene transfer induced vascular tube formation in vitro 
(Fig. 4E, quantified in the right panel as total tube 
length /field (µM)) and vessel formation in vivo (Fig. 4F, 
quantified in the right panel as capillary density) when 
compared to controls. CD144 immunofluorescence 
staining verified the presence of differentiated cells in 
in vivo vascular tubes and demonstrated that QKI-5 
over-expressing iPS cells displayed well-formed vascular 
structures and enhanced engraftment ability when 
compared to the control cells (Fig. 4G). Moreover, the 
nascent vessels in vivo (matrigel plugs) were stabilised 
by pericytes/vascular smooth muscle cells in the pres-
ence of QKI-5 as smooth muscle alpha- actin (SMA) 
staining is shown in Supplementary Figure S7. These 
results demonstrate that QKI-5 induced the angiogene-
sis in both in vitro and in vivo Matrigel plug assays. 
 
QKI-5 significantly improved neovasculariza-
tion and blood flow recovery in the hind limb 
ischemic model 
ECs derived from mouse iPS cells (iPS-ECs CTL) or iPS 
ECs overexpressing QKI-5 (iPS- ECs OE-QKI-5) were la-
belled with Vybrant and injected intramuscularly imme-
diately after induction of hind limb ischemia in mice. 
PBS was also used as an additional control. After 7 and 
14 days, delivery of iPS- ECs OE-QKI-5 improved neovas-
cularization and promoted significantly higher blood 
flow in the ischemic limbs compared to the non-
modified, iPS-ECs controls or PBS controls (Fig. 5A-D). 
Limbs receiving iPS- ECs OE-QKI-5 also displayed signifi-
cantly higher capillary numbers in the musculature in 
comparison to the controls (Fig. 5E, F) as shown by 
staining of adductor muscle sections with CD144 (Fig. 
5G) and CD31 (Supplementary Fig. S8A) in immunoposi-
tive vessel profiles. Notably, engrafted iPS- ECs OE-QKI-
5 displayed a typical vascular architecture while in the 
PBS control experiments a random pattern and no vas-
cular structures were observed (Fig. 5E, F). 
Finally, when adductor muscle sections from iPS-ECs 
CTL or iPS- ECs OE-QKI-5 injected animals were stained 
and quantified with Vybrant and EC markers, iPS- ECs 
OE-QKI-5 were found to display an enhanced engraft-
ment ability compared to controls (Fig. 5H and Supple-
mentary Fig. S8B). These results indicate that iPS- ECs 
OE-QKI-5 display characteristic endothelial functions 
when tested in vivo. Importantly, no tumours have been 
detected in any animals during the duration of these 
experiments highlighting that these pluripotent stem 
cells were fully differentiated into ECs. 
 
QKI-5 has a key role in EC differentiation de-
rived from human iPS cells 
Generation of high-fidelity and stable EC populations, 
derived from human pluripotent cells, is a major limita-
tion that the EC differentiation and cell reprogramming 
field are facing at the moment. Thus, we investigated 
whether QKI-5 has a role in EC differentiation derived 
from human iPS cells. Human iPS cells were generated 
and differentiated in low attachment plates using 
StemPro serum free media supplemented with BMP4, 
Activin A, FGF and VEGF for 5 days. Then, a KDR positive 
population was selected and cultured in Fibronectin 
QKI-5 regulates EC differentiation and angiogenesis 
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coated plates supplemented with EGM-2 media for 3 to 
9 days. The derived human iPS-ECs displayed a typical 
pattern of EC specific markers such as CD144, CD31, 
eNOS, and vWF (Fig. 6A). The efficiency of EC differenti-
ation from human iPS cells was 62% as shown by FACs 
analysis for the positive cells for the EC marker CD144 
(Fig 6B). QKI-5 was expressed during EC differentiation 
from human iPS cells in parallel with VE-cadherin ex-
pression (Fig. 6C, D). QKI-5 overexpression by lentiviral 
gene transfer significantly induced the expression of the 
EC markers CD144, CD31 and eNOS (Fig. 6E, F, and sig-
naling of VEGFR (KDR), VEGFA and STAT3 during EC dif-
ferentiation (Fig. 6G). Further data from luciferase as-
says also confirmed that QKI-5 induced the transcrip-
tional activation of CD144 and VEGFR in human cells 
(Fig. 6H, I). In contrast, knockdown of QKI-5 by shRNA 
suppressed the transcriptional activation of both CD144 
and VEGFR (Fig. 6H, I). Importantly, QKI-5 only induced 
the expression of arterial specific EC marker and not the 
expression of venous and lymphatic markers (Fig. 6J). 
This data reveal that QKI-5 is implicated in EC differenti-
ation from human iPS cells towards an arterial EC speci-
fication. 
 
Human iPS-ECs overexpressing QKI-5 induced 
angiogenesis in vivo 
Since iPS-ECs in the presence of QKI-5 maintained a 
stable phenotype for many passages without drifting to 
various non-endothelial phenotypes (as it has already 
been shown in Fig 2), we further investigated whether 
QKI-5 had a similar role in mature ECs. For these exper-
iments, QKI-5 was overexpressed in Human Umbilical 
Vein Endothelial Cells (HUVECs) by lentiviral gene trans-
fer. These lentiviral constructs expressed mCherry, and 
the efficiency of infection was monitored by in vivo im-
aging using a fluorescence microscope (Fig. 7A). Indeed, 
QKI-5 was highly overexpressed in these mature ECs 
(Fig. 7B) and was able to induce further the expression 
of CD144 and VEGFA in both protein and mRNA levels 
(Fig. 7C, D). Importantly, QKI-5 overexpression did not 
induce the expression of non-EC markers such as SMA 
and SM22 (Fig. 7C). These results highlight that QKI-5 
induces EC differentiation from human iPS cells and, in 
parallel, has an important role in the maintenance of 
the EC phenotype in both differentiated and mature 
ECs. Additional experiments with Matrigel plus assays in 
vivo provided further support to the above findings. 
Human iPS-ECs overexpressing QKI-5 significantly in-
duced angiogenesis only 7 days after subcutaneous in-
jection of ECs OE- QKI-5- iPS cells labeled with Vybrant 
cell surface marker in SCID mice, in comparison to the 
iPS-ECs CTL expressing an empty lentiviral vector (HE 
staining in Fig. 7E). CD31 immunofluorescence staining 
confirmed the presence of differentiated cells in in vivo 
vascular tubes and demonstrated that QKI-5 over-
expressing iPS cells displayed well-formed vascular 
structures (Fig. 7G) and enhanced engraftment ability 
when co-stained with CD144 and Vybrant compared to 
the control cells (Fig. 7F, H). In addition, a human specif-
ic antibody for CD31 was used to stain exclusively the 
human cells in the Matrigel plugs and co-stained with 
the Vybrant in order to confirm the present of the hu-
man cells and the specificity of the Vybrant labelling 
(Fig. 7I). These results clearly demonstrate that QKI-5 
induced angiogenesis in vivo Matrigel plug assays high-
lighting its pivotal role in EC differentiation derived 
from human iPS cells. 
 
DISCUSSION 
 
iPS cells represent an attractive cellular approach for 
regenerative medicine today since they can be used to 
generate therapeutic cells of almost any type and, im-
portantly, can be harnessed as patient-specific cells 
towards autologous cell therapy. In this study, using the 
model of iPS cells differentiation towards ECs, the RNA-
binding protein QKI-5 was found to be an important 
regulator of VE-cadherin stabilisation and VEGFR2 tran-
scriptional activation during the EC differentiation pro-
cess. Notably, QKI-5 overexpression induced the activa-
tion of EC markers, whilst knockdown by shRNA sup-
pressed EC differentiation. In the present study, the role 
of QKI-5 has been elucidated in EC differentiation from 
iPS cells. iPS cells have been generated based on a high-
ly efficient approach, fully characterized and forced to 
differentiate towards ECs. QKI-5 was found to be in-
duced during EC differentiation from iPS cells, and its 
expression was shown to be maintained at high levels in 
mature ECs. It has been demonstrated that QKI-5 plays 
a role in the induction and stabilisation of CD144 and 
activation of VEGFR-regulatory binding sites AP1 and 
STAT3 and induction of STAT3 phosphorylation. Im-
portantly, QKI-5 modulated the activation of VEGFR 
through direct binding of the 3’ UTR region of STAT3. 
The notion that QKI-5 indeed played an important role 
during EC differentiation was further supported from 
additional data which clearly demonstrated that knock-
down of QKI-5 resulted in inhibition of angiogenesis in 
vivo. Remarkably, ECs derived from iPS overexpressing 
QKI-5 improved neovascularization and blood flow re-
covery (almost 100%) in a hind limb ischemia model by 
showing an enhanced engraftment capacity when com-
pared to non-modified iPS-ECs or PBS control groups. 
Notably, human iPS cells overexpressing QKI-5 induced 
angiogenesis in Matrigel plug assays in vivo only seven 
days after subcutaneously injection in SCID mice, high-
lighting a clear functional benefit of QKI-5 in neovascu-
larization, blood flow recovery and angiogenesis. 
RNA-binding proteins add an additional layer of 
complexity to a series of events, which include pro-
cessing and splicing of pre-mRNA, export to the cyto-
plasm, quality control assessment of mRNA through 
translation, message decay and stabilization, and trans-
lational repression and de-repression  [44]. All of these 
events, from initiation of transcription by key transcrip-
tion factors, to the stability and effective translation of 
the message, are regulated by the presence of specific 
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nucleotide sequences which are bound by specific RNA-
binding proteins  [45]. 
CD144 is a strictly endothelial specific adhesion 
molecule and is of vital importance in maintaining and 
controlling the endothelial phenotype through appro-
priate cell-cell contacts  [16]. CD144 is essential during 
embryonic angiogenesis and, thus, the elucidation of 
the underlying mechanisms that regulate CD144 are 
important in understanding the functions permeating 
vascular permeability, cell proliferation, apoptosis and 
modulation of VEGFR. A recent study has shown that 
QKI directly binds to the 3’ UTR of CD144 [46]. In our 
study, we provide further support to the above notion 
that QKI-5 induced the mRNA stabilisation of CD144. 
           VEGF-A is one of the earliest markers for the 
endothelial lineage during development  [47, 48] and 
this growth factor is also critical for vascular repair and 
neovascularization  [49]. The data obtained in this study 
indicates that QKI-5 regulates EC expression of VEGF-A 
and autocrine stimulation of VEGFR and this pathway is 
controlled, at least in part, through STAT3 activation 
and phosphorylation. Interestingly, knockdown of 
STAT3 by shRNA ablated QKI-5-mediated activation of 
the VEGFR and subsequent expression of EC markers. It 
has been reported that constitutive STAT3 activity up-
regulates VEGFR  [50], while STAT3 protein binds to the 
VEGFR promoter inducing VEGFR promoter activity  
[50]. Interestingly, QKI-5 regulates the expression of 
STAT3 through direct binding in the 3’UTR leading to 
mRNA stabilisation.  Notably, the KH DOMAIN-mutant 
QKI-5 construct did not induce the expression of the EC 
markers, STAT3 signalling when it was overexpressed in 
iPS cells. Importantly, QKI-5 was unable to activate the 
3’UTR of STAT3 when the QKI motif was deleted. These 
results demonstrate that QKI-5 binds to the 3’UTR of 
STAT3 in the JAK1-STAT3 signalling pathway and regu-
lates EC differentiation towards an arterial lineage. 
It has previously been reported that QKI-5 knockout 
mice display a range of blood vessel defects during de-
velopment which result in embryonic lethality  [39]. 
Additional studies of the extraembryonic yolk sac have 
also reported that QKI regulates visceral endoderm dif-
ferentiated function at the cellular level, including the 
local synthesis of retinoic acid (RA [29]), which then 
exerts paracrine control of ECs within the adjacent 
mesoderm. QKI is also highly expressed during normal 
cardiac development, particularly in the outflow tract, 
suggesting potentially unique functions in the develop-
ing heart [51] and vascular smooth muscle cell devel-
opment  [52]. Taken together, this is strong evidence 
that QKI is highly conserved  in the early embryo 
throughout the evolution of non-vertebrate and verte-
brate organisms  [29]. The role of QKI in the adult or-
ganism is less well-appreciated, although there is evi-
dence that it could have a role in vascular smooth mus-
cle cell phenotypic plasticity and can ameliorate patho-
genic, fibroproliferative responses to vascular injury  
[53]. 
The present study provides strong evidence that 
QKI-5 is capable of inducing differentiation towards ECs 
and that, in parallel, regulates angiogenesis in both in 
vitro and in vitro Matrigel plus assays, even in the ab-
sence of exogenous VEGF. At the moment, the potential 
of iPS cells to differentiate towards therapeutic cells is 
only based on directed empiricism, while they are total-
ly dependent on combinations of growth factors, media, 
and matrices to favour the desired lineage. In regards to 
vascular regeneration, it is important to understand the 
key regulatory pathways such as epigenetic alterations, 
transcriptional activity, and RNA-binding patterns asso-
ciated with the differentiation processes. In particular, 
although there has been significant progression in the 
field  [54], there are not any fully defined protocols to 
generate high-fidelity and stable endothelial cells from 
human pluripotent stem cells at the moment. This is a 
major limitation of generating pure populations of reju-
venated EC cells to be used for drug screening and cell-
based therapies. Indeed, QKI-5 is a very interesting can-
didate, which holds the potential to derive stable popu-
lations of functional ECs. Specifically, the transcription 
factor ETS1 is implicated in the induction of the expres-
sion of QKI-5 during early stages of EC differentiation. 
QKI-5 is also acting as a splicing factor involved in the 
regulation of numerous signalling pathways.  Data from 
our lab also showed that QKI-5 induced the splicing fac-
tor SF3B1 during EC differentiation (Supplementary 
Figure S9). Importantly, SF3B1 is induced in a time de-
pendent manner during EC differentiation from iPS cells 
(Supplementary Fig. S10), indicating that QKI-5 is likely 
to be an important splicing regulator of EC differentia-
tion. Notably, a number of QKI splicing isoforms have 
been reported, although their function(s) are not clearly 
defined. Additional studies are clearly required to shed 
light on the precise functions of the different QKI splic-
ing isoforms. Interestingly, a recent paper has reported 
that QKI plays a remarkably dynamic role in regulating 
hundreds of circular RNAs (circRNAs) during human 
epithelial to mesenchymal transition (EMT), whilst QKI 
itself is regulated during EMT  [16]. Therefore, it is 
tempting to speculate that precise regulation of QKI-5 
during EC differentiation will provide fully defined ex-
perimental protocols, which could reproducibly guide 
iPS cells to a vascular lineage  [55, 56] and, thereby, 
enable clinical application  [57-59]. In addition, it would 
be very interesting to investigate the role of QKI and its 
mRNA splicing isoforms in disease models, such as ath-
erosclerosis and diabetes, where the endothelial func-
tion is impaired. 
         In summary, our data strongly supports the no-
tion that QKI-5 is induced during EC differentiation, re-
sulting in stabilisation of STAT3 expression through di-
rect binding to the 3’ UTR region of STAT3, modulation 
of VEGFR transcriptional activation and VEGF secretion. 
Markedly, iPS-ECs overexpressing QKI-5 significantly 
improved angiogenesis and neovascularization and 
blood flow recovery in experimental hind limb ischemia 
(Supplementary Fig. S9) highlighting a clear functional 
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benefit. This study provides support to the growing 
consensus that elucidating the molecular mechanisms 
underlying EC differentiation will ultimately advance 
stem cell regenerative therapy towards treating cardio-
vascular disease. 
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Figure 1. Induced Pluripotent Stem Cell Differentiation towards endothelial cells. Mouse iPS cells were cultured on 
0.02% gelatin with media supplemented with LIF (Leukaemia inhibitory factor) to maintain pluripotency. To induce EC 
differentiation iPS cells were seeded onto plates coated with collagen IV and differentiation media supplemented 
with 25ng/ml VEGF (DM+V). (A) Schematic diagram showing differentiation process. (B) Images show morphology of 
iPS cells (left panel) and of their differentiated EC counterparts (right panel) Scale bar: 50μm. (C) FACs analysis show-
ing expression of CD144 (left panel) and CD31 (right panel) of ECs derived from iPS cells. (D,F) EC marker expression 
increased in a time dependent manner during differentiation at both mRNA and protein level, whilst the pluripotent 
marker OCT4 decreased during EC differentiation in a time-dependent manner (data are mean ±SEM (n=3), *p<0.05, 
*** p<0.001). (E) Immunofluorescence confocal image showing that the 6 days differentiated ECs express the EC spe-
cific marker CD144, Scale bar: 50μm. (G) iPS-ECs expressed EC markers CD144, FLK-1, eNOS, and VWF as shown by 
confocal immunofluorescent images, Scale bar: 50μm. (H) The transcription factor STAT3 was progressively expressed 
during EC differentiation, (data are mean ±SEM (n=3), *p<0.05). 
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Figure 2. The RNA binding protein QKI-5 is induced during EC differentiation from iPS cells. (A) RNA binding protein 
QKI-5 was induced during EC differentiation in parallel with the EC markers CD144 and CD31.The expression levels of 
QKI-6 and QKI-7 were not changed or decreased, respectively.  (B) Western Blots showing that QKI-5 protein was pro-
gressively expressed in parallel with the EC marker CD144 and the transcription factor STAT3 in time point experi-
ments from 0 to 10 days during EC differentiation. (C) Immunofluorescence staining showing that QKI-5 is localized in 
the nucleus and in parallel with CD144 in differentiated ECs (D), (Scale bar, 50 µm) and (E) with CD31 in mature ECs 
(HUVECs), Scale bar, 25 µm. (F) iPS-ECs were infected or transfected on day 4 with QKI-5 or an empty vector. 48 h 
later QKI-5 overexpression induced mRNA expression of endothelial markers CD144, CD31, eNOS, VEGFA, and the 
transcription factor STAT3. (G) QKI-5 induced protein expression of CD144. (H) iPS-ECs were differentiated for 3 days 
and transfections with the reporter of CD144 (VE-cadherin) construct (pGL3-Luc-CD144) in the presence or absence of 
QKI-5 were performed. Cells were harvested on day 5 of EC differentiation when luciferase assays demonstrated that 
QKI-5 induced transcriptional activation of the VE-cadherin promoter. (I) iPS-ECs were differentiated for 4 days and 
transfected with QKI-5 or an empty vector.  48 hours later QKI-5 overexpression directed differentiation towards ar-
terial ECs (Ephrin B2) specifically and not towards venous (CoupTFII) or lymphatic (Lyve1) ECs or other tissues such as 
nerve (Nestin), cardiac (Mef2c) or smooth muscle cell (SMA), (data are means ± SEM. (n=3), *p<0.05, ** p<0.01, *** 
p<0.001). 
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Figure 3. QKI-5 induced VEGF Receptor 2 (VEGFR2) activation and VEGF secretion through direct binding of the 
3’UTR region of STAT3 
Overexpression of QKI-5 by lentiviral gene transfer induced the secretion of VEGF on day 6 of the EC differentiation 
process (A) and the transcriptional activation of the VEGFR2 (B). (C) Real time PCR data showing that QKI-5 leads to 
activation of VEGFA, JAK-1, STAT3 and AP1. (D) Western blots showing that overexpression of QKI-5 induced the ex-
pression of EC markers CD144, and CD31 in parallel to induction of JAK-1, STAT3 and phosphorylation of STAT3 (quan-
tification in E). (F) STAT3 was knocked down by shRNA on day 3 of EC differentiation, and QKI-5 was overexpressed 
next day. Real data PCR data reveal that STAT3 knocked down ablated activation of EC markers CD31, CD144, eNOS, 
and VEGFA mediated by QKI-5. The cells were harvested on day 6 of EC differentiation. (G) Luciferase assays have 
shown that QKI-5 activated the 3’UTR of STAT3. QKI-5 was unable to activate the 3’UTR of STAT3 when the QKI motif 
was deleted. (G, lower panel) RNA binding assays have confirmed that QKI binds directly to the 3’UTR of STAT3. (H) 
When differentiated ECs were treated with Actinomycin D in a time point experiment from 0 to 24 hours STAT3 ex-
pression was stabilised as a decay curve is shown (data are means ± SEM. (n=3), *p<0.05). 
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Figure 4. QKI-5 plays a critical role during EC differentiation and vascular tube formation both in vitro and in vivo. 
QKI-5 knockdown by shRNA in iPS-ECs at day 4 of differentiation resulted in suppression of (A) mRNA expression of 
the EC markers CD144 and CD31 (data are means ± SEM. (n=3), *p<0.05), and (B) protein expression of CD144 and 
the transcription factor STAT3, when assessed on day 6. (C) shRNA knockdown of QKI-5 resulted in suppression of the 
transcriptional activity of the VEGFR2 during EC differentiation, as shown by luciferase assays. Non targeting (NT) con-
trol for knockdown experiments using shRNA. These experiments were performed on day 3 and analysed on day 5 of 
EC differentiation (data are means ± SEM. (n=3), *p<0.05). (D) shRNA knockdown of QKI-5 during EC differentiation 
suppressed the formation of vascular-like tubes in vivo in Matrigel plug assays. iPS-ECs were infected with QKI-5 
shRNA on day 4 of EC differentiation, and 48 h later, mixed with Matrigel and subcutaneous injected in to mice, prior 
to analysis of Matrigel plugs 7 days later; Scale bar, 50 µm. iPS cells were seeded on collagen IV-coated plates and 
cultured in differentiated media in the absence of VEGF for 4 days when QKI-5 or control plasmids were introduced 
by lentiviral gene transfer. Two days later, cells were mixed with Matrigel for in vitro plug assays. (E) QKI-5 formed 
vascular structures within a few hours in vitro in comparison to the control where less defined vascular structures 
were observed (e, left panel, with right panel showing quantification as total tube length/field (µm) (data are means ± 
SEM. (n=3), *p<0.05). (F) similarly, cells were subjected to Matrigel plug assays in vivo which showed that QKI-5-
expressing cells form well defined vascular structures at 7 days in comparison to the control where less well-formed 
vascular structures were observed (f, left panel, with quantification of capillary density (number / mm [2]) in the right 
panel), (data are means ± SEM. (n=3), *p<0.05). (G)  Frozen sections from the in vivo Matrigel plugs were stained for 
CD144 to demonstrate that over-expression of QKI-5 induced the formation of vascular structures and enhanced en-
graftment ability compared to the control cells (data are means ± SEM. (n=3), *p<0.05).  Scale bar, 50 µm. 
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Figure 5. QKI-5 significantly improved neovascularization and blood flow recovery in experimental hind limb is-
chemia. ECs derived from iPS cells (iPS-ECs), iPS-ECs overexpressing QKI-5 (iPS-QKI-5-ECs) labelled with Vybrant, or 
PBS as a control were injected intramuscularly immediately after induction of hind limb ischemia. (A-C) Laser Doppler 
images of blood flow (BF) in the lower limbs of mice in prone position, with the ischemic leg highlighted by the white 
rectangle.  (D) Time course of BF recovery in the ischemic foot (calculated as a percentage ratio between ischemic 
foot BF and the contralateral foot BF) for each of the three conditions. Statistical analysis shows significantly higher 
BF recovery in the iPS-EC QKI-5 treated mice at 7 and 14 days in comparison with PBS control and also comparing iPS-
ECs to iPS-ECs- OE-QKI-5; Bonferroni post test (to one way anova) confirms significant difference after 14 days be-
tween iPS-ECs and iPS-ECs overexpressing QKI-5; * p<0.05, ** p<0.01, *** p<0.001 [data are means ± SEM (n=3)] (E-F) 
Sections of adductor muscles were stained with CD144 or CD31 antibody and (G) capillary density expressed as capil-
lary number per mm [2] , and (E,F) further co-stained with CD144 (green) and Vybrant (red) prior to (H) quantifica-
tion, (and for CD31 please see Supplementary Figure S4A and B) * p<0.05, *** p<0.001 data are mean ± SEM, quanti-
fication from 4 random microscopic fields at x40, scale: 50μm). 
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Figure 6. QKI-5 has a key role in EC differentiation derived from human iPS cells. (A) Human iPS cells were generated 
and differentiated on low attachment plates using StemPro serum free media supplemented with BMP4, Activin A, 
FGF and VEGF for 5 days. KDR (VEGFR) positive population was selected using MicroBeads and cultured on Fibron-
ectin coated plates supplemented with EGM-2 media for 3 to 9 days. iPS-ECs derived cells expressed a typical pattern 
for EC specific markers CD144, CD31, eNOS, and vWF as immunofluorescence images shown. (B) FACs analysis show-
ing cells positive for EC specific marker CD144 (C-D) QKI-5 was expressed during EC differentiation in parallel with VE-
cadherin expression in mRNA level. (E-G) QKI-5 was overexpressed by lentiviral gene transfer in human iPS cells on 
day 3 after KDR selection and the cells were harvesting on day 6 of EC differentiation showing a significant induction 
of the EC markers CD144, CD31 and eNOS, and signalling of VEGFR (KDR), VEGFA and STAT3 as western blots and real 
time data shown. (H-I) Luciferase assays shown that QKI-5 induced the transcriptional activation of CD144 and VEGFR. 
(J) Overexpression of QKI-5 directs differentiation towards arterial EC as cells express specific marker Ephrin B2 and 
not venous (CoupTFII) or lymphatic (Lyve1) EC markers, (data are means ± SEM. (n=3), *p<0.05, ** p<0.01). 
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Figure 7. QKI-5 induced CD144 and VEGFA expression in HUVECs and Human iPS-ECs overexpressing QKI-5 induced 
angiogenesis in vivo. (A) QKI-5 was overexpressed in HUVECs by lentiviral gene transfer. The efficiency of infection 
was monitored by the mCherry expression. (B-C) QKI-5 was highly overexpressed in mature ECs and induced further 
the expression of CD144 and VEGFA (C-D), but it did not induce non-EC markers such as SMA and SM22 in the mRNA 
level (D), (data are means ± SEM. (n=3), *p<0.05, ** p<0.01).  Scale bar, 50 µm. Human iPS-ECs were forced to over-
express QKI-5 by lentiviral gene transfer on day 3 of EC differentiation after KDR selection. On day 6 iPS-ECs overex-
pressing an empty lentiviral vector or iPS-QKI-5-ECs were labelled with Vybrant Cell Labelling and subcutaneously 
injected in SCID mice. (E) iPS-QKI-5-ECs significantly formed well-defined vascular structures at 7 days in comparison 
to the control where less or none formed vascular structures were observed as H&E staining shown. (F) Frozen sec-
tion of CD31 immunofluorescence staining confirmed the presence of differentiated cells in in vivo vascular tubes. (G-
H) Enhanced engraftment ability of iPS-QKI-5-ECs was observed when co-stained with CD144 and Vybrant compared 
to the control iPS-ECs. Scale bar, 50 µm. (I) Further staining using human specific CD31 antibody confirms the pres-
ence of human cells and specificity of the Vybrant in samples seen in (G-H). 
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Graphical Abstract 
The RNA binding protein QKI-5 is induced during EC differentiation from iPS cells. RNA binding protein QKI-5 was in-
duced during EC differentiation in parallel with the EC marker CD144. Immunofluorescence staining showing that QKI-
5 is localized in the nucleus and stained in parallel with CD144 in differentiated ECs, (Scale bar, 50 µm). 
 
 
